Currently, Pfizer Inc. manufactures Oxbryta. However, they are in the process of voluntarily withdrawing it from the market.
According to recent data, Pfizer's assessment is that the benefits of Oxbryta do not outweigh the risks for sickle cell patients. Because of this, the company announced on September 26, 2024, that it would cease distribution, discontinue all active clinical trials, and end expanded access programs for Oxbryta.
